Authors

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Dr Smith on Implications of Data From the frontMIND Trial in DLBCL

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Oncology Providers Face Rising Pressures From Payers Over Therapy Choices

Insurance companies are beginning to indirectly manage prescribing to better manage costs.

Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung Cancer

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

Digital Health and Process Improvements Enhance Community-Based Patient Care

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

CMS Releases Final CY 2026 Hospital Outpatient Prospective Payment System (OPPS): Implications for Nuclear Medicine

The Centers for Medicare and Medicaid released the final rule for the CY Hospital OPPS, which will take effect in 2026.

Final Takeaways – Sequencing, Counseling, and Prevention

Weigh nivolumab–ipilimumab benefits versus immune toxicities in HCC, factoring patient comorbidities, access, preferences, and the urgent need for predictive biomarkers.

Not All Stage I and II Endometrial Cancers Are Alike

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

New Framework for Genetic Testing in Prostate Cancer Takes Shape

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

New Breast Center at UI Health Care Aims to Ease the Cancer Journey for Patients

The new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.

The Evolving Health Care Landscape and the Oncologist’s Role in Policy Engagement

In her latest OncologyFellows column, Jill Gilbert, MD, discusses how oncologists can influence large health care decisions and policy.

Normalizing Motherhood in Medicine

Hematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.

Breast Cancer Drug Is Effective for Treatment-Resistant Uterine Cancer

A Yale School of Medicine study showed sacituzumab govitecan could provide new options for treatment-resistant uterine cancer.

Tebentafusp Displays Long-Term Survival Benefit in HLA-A*02:01+ Uveal Melanoma

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Breaking New Ground in Biological Therapies for Cancer

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.

Tebentafusp Displays Long-Term Survival Benefit in HLA-A*02:01+ Uveal Melanoma

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

How Advancing the Science of Bladder Cancer Aims to Transform Patients’ Lives

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer Disparities

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

Prevention Matters: Offit and the Birth of Cancer Genetics

Kenneth Offit, MD, MPH, is a pioneering cancer geneticist whose groundbreaking work has shaped how hereditary cancer is understood, prevented, and managed.

Improving outcomes in metastatic pancreatic cancer

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Surgical Intervention Provides the Foundation for Exploring Immunotherapy in Glioblastoma

Because the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Barbara Ann Karmanos Cancer Institute and Wayne State University Name Boris C. Pasche, MD, PhD, FACP, President and Chief Executive Officer

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

Investigators Explore Immunotherapy for NETs as Incidence Grows

To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.

Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.

Pandemic Inspires New Outreach Program

As oncologists, we are here to help patients and their families as much as we can. That is why we went into cancer medicine. It is what we do every day. Until the coronavirus disease 2019 pandemic knocked on our doors.

Evolving Psychosocial Care Models Step Forward as the Next Targeted Cancer Therapy

During this search for a breast cancer support system, my mother also investigated complementary therapies that peers had used to help cope with their fears, adverse effects, and feelings of helplessness.